Lancet Respir Med:异氟醚用于ICU患者镇静的效果不劣于丙泊酚!

2021-09-14 Nebula MedSci原创

异氟醚用于ICU有创呼吸的患者镇静的效果不劣于丙泊酚!

既往研究表明,异氟醚可用于重症监护病房 (ICU) 患者的镇静,但评估异氟醚疗效的前瞻性研究很少。本研究旨在测试异氟醚用于 ICU 患者的镇静作用是否不劣于丙泊酚的。

这是一项随机对照的、开放标签的非劣效性 3 期试验,在德国(21 个地点)和斯洛文尼亚(3 个地点)的 ICU 进行有创通气的成人(≥18岁)中,评估了异氟醚 vs 丙泊酚应用长达 54 小时的有效性和安全性。主要终点是 RASS 镇静评分 -1~-4分的时间比(在镇静合格至少 12 小时的患者中评估)。次要终点是阿片类药物的需求、自主呼吸、起床和拔管时间以及不良反应。

2017年7月2日至2020年1月12日,共招募了338位患者,其中301位(89%)被随机分至异氟醚组(n=150)或丙泊酚组(n=151)。两组各有 146 位(97%)患者完成了 24 小时随访。异氟醚组的 146 位(97%)和丙泊酚组的 148 位(98%)患者被纳入了主要终点的预协议分析。

每组达到目标镇静水平的患者比例

异氟醚组在 RASS 目标范围内的最小二乘平均时间百分比为 90.7% (95% CI 86.8-94.6),丙泊酚组的为 91.1% (87.2-95.1)。采用异氟醚镇静的整个期间,阿片类药物的应用剂量比丙泊酚组的低 29%(0.22 [0.12-0.34] vs 0.32 [0.21-0.42] mg/kg·h 吗啡当量,p=0.0036),而且第 1 天的自主呼吸更频繁(优势比[OR] 1.72 [1.12-2.64],广义混合线性模型 p=0.013)。第 2 天异氟醚组的插管时间较短,中位起床速度更快(20 vs 30 分钟;p=0.0011)。

镇静过程中吗啡当量剂量强度和BPS评分

最常见的不良事件(异氟醚组 vs 丙泊酚组)有高血压(7% vs 1%)、谵妄(5% vs 5%)、少尿(5% vs 4%)和房颤(3% vs 3%)。

综上,该研究结果支持在有镇静临床需要的有创通气患者中使用异氟醚

原始出处:

Meiser Andreas,Volk Thomas,Wallenborn Jan et al. Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomised controlled, non-inferiority trial.[J] .Lancet Respir Med, 2021, https://doi.org/10.1016/S2213-2600(21)00323-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
    2022-01-24 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
    2021-09-15 ms4000001729026290

    学习#学习#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
    2021-09-14 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
    2021-09-14 daye

    的确很好,还要好好学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
    2021-09-14 ms2000000188453438

    Ok

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1831301, encodeId=60471831301ab, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 24 08:16:45 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1973975, encodeId=82cf19e3975d7, content=<a href='/topic/show?id=827b49808cd' target=_blank style='color:#2F92EE;'>#异氟醚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49808, encryptionId=827b49808cd, topicName=异氟醚)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/0EDD6BA8A8C6A0C23E8ABC8BA5331A25/100, createdBy=d37d2500154, createdName=ms5106640509429053, createdTime=Fri Feb 04 13:16:45 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595390, encodeId=bad41595390c0, content=<a href='/topic/show?id=44b993e977' target=_blank style='color:#2F92EE;'>#ICU患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9379, encryptionId=44b993e977, topicName=ICU患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=003c18235152, createdName=piaojinhua, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611253, encodeId=58551611253f7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 16 11:16:45 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051415, encodeId=e7a910514150f, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c59a5604039, createdName=ms4000001729026290, createdTime=Wed Sep 15 09:45:28 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052718, encodeId=d47a1052e18d5, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Tue Sep 14 23:16:45 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051295, encodeId=29641051295fe, content=的确很好,还要好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/lbU9Ut4TY88RUNuwCiaHzIuHP8GzI1gEo9OVleMryQK4S8ntwhyWFmFYYZZsdQeXNrSKzFsJZ5YVoXMxaTsFhpQ/132, createdBy=199c5324866, createdName=daye, createdTime=Tue Sep 14 22:21:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051284, encodeId=34c51051284b4, content=Ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11125605934, createdName=ms2000000188453438, createdTime=Tue Sep 14 21:59:42 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051262, encodeId=989f105126284, content=学习医学, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210313/9df56058b3964a8cac82563f95f0389d/c1b478592e8e4463bef44d32712e98fd.jpg, createdBy=ea905324251, createdName=SR~young海东, createdTime=Tue Sep 14 21:00:56 CST 2021, time=2021-09-14, status=1, ipAttribution=)]
    2021-09-14 SR~young海东

    学习医学

    0

相关资讯

NEJM:右美托咪定或丙泊酚用于机械通气的脓毒症成人镇静的疗效比较

在机械通气的脓毒症成人中,建议采用轻度镇静方法进行治疗,接受右美托咪定的患者的预后与接受异丙酚的患者预后无明显差异。

2019 ASIPP指南:接受介入性疼痛治疗患者的镇静和禁食状态

2019年5月,美国介入疼痛医师协会(ASIPP)发布了接受介入性疼痛治疗患者的镇静和禁食状态指南。许多接受介入性疼痛治疗的患者每日服用的药物包括止痛药,肌肉松弛剂以及其他在围术期具有明显协同作用的药物。本文主要内容涉及接受介入性疼痛治疗患者的镇静和禁食情况。

芬太尼特殊剂型的使用注意事项及相互作用

阿片受体激动药包括阿片生物碱类镇痛药如吗啡,及人工合成镇痛药如芬太尼、舒芬太尼、瑞芬太尼,临床可用于疼痛的治疗等。芬太尼是目前临床常用药之一,主要激动μ受体,属于短效镇痛药。其同类药物还有舒芬太尼、瑞芬太尼等。

NEJM:轻度镇静或不镇静对ICU通气患者死亡率的影响

在ICU机械通气患者中,无镇静或每日中断轻度镇静组间90天的死亡率无显著差异

NEJM:右美托咪定单药用于危重病人的早期镇静

在ICU接受机械通气的患者中,早期接受右旋美托咪定镇静剂的患者在90天时的死亡率与常规护理组相似,需要补充镇静剂才能达到规定的镇静剂水平。右美托咪啶组报告的不良事件多于常规护理组

烧伤后颏颈胸瘢痕挛缩患者右美托咪定镇静纤支镜引导下经鼻气管插管的体会

颏、颈、胸重度烧伤患者,临床表现为颈部瘢痕挛缩严重,下颌与前胸瘢痕粘连,患者张口困难,后仰受限。此类患者存在面罩通气困难,声门显露困难,气道表麻困难等问题,严重影响手术,威胁患者健康,实施气管内插管对麻醉医生是严峻的挑战。山东大学附属省立医院麻醉科近期采用自制的OLYMPUSLF-DP型号纤支镜气道内表麻设备先实施气管内表麻,然后再使用右美托咪定镇静,纤支镜引导下成功完成经鼻气管插管,插管过程患者